Local biopharmaceutical company Vividion Therapeutics has raised $50 million in a Series A funding round.
The funding was led by two top-tier venture capital firms, ARCH Venture Partners and Versant Ventures, and also included Cardinal Partners.
Vividion, which is tapping into technology developed at The Scripps Research Institute, says it has developed a novel drug discovery platform that applies chemical proteomics to treat major unmet clinical needs.
The company’s technology was spun out of the lab of Ben Cravatt, Professor at The Scripps Research Institute in La Jolla, according to its investors.
